Significant CV risk reductions across the spectrum of Cardio-Vascular Disease

Diabetes

• CARDS: Atorvastatin 10 mg provided a significant reduction in CV events in patients with type 2 diabetes and ≥1 risk factor compared with placebo.¹

Incidence of major CV events*

Coronary Heart Disease & Diabetes

• TNT (diabetes): Atorvastatin 80 mg reduced the risk of major CV events by 25% (p=0.026) compared with Atorvastatin 10 mg in a post hoc analysis of patients with stable CHD and type 2 diabetes.²

Incidence of major CV events^##

Patients with CV risk factors⁵

• ASCOT-LLA trial:In patients with hypertension and ≥3 additional risk factors LIPITOR^® 10 mg reduced the risk of non-fatal MI and fatal CHD by 36% compared to placebo.⁵^

Coronary Heart Disease

• TNT^ð trial: In patients with CHD, Lipitor^® 80mg reduced the risk of First Major Cardio Vascular Event by 22% (compared with LIPITOR^® 10 mg): ⁸

Acute Coronary Syndrome

• PROVE-IT ^ß : Atorvastatin 80 mg reduced the risk of death or a major CV event^Ω by 16% (p=0.005) compared with pravastatin 40 mg in patients with acute coronary syndrome.⁹

Incidence of death or major CV events ^Ω

Coronary Heart Disease

• The ALLIANCE^‡ Study: Clinical Outcomes in Managed-Care Patients With Coronary Heart Disease Treated Aggressively in Lipid-Lowering Disease Management Clinics.⁷

Abbreviations:

* Primary endpoint=time to first occurrence of a major CV event, (MI including silent MI, unstable angina, acute fatal CHD, resuscilated cardiac arrest, coronary revascularization, or stroke)

** ARR: Absolute Risk Reduction

# RRR: Relative Risk Reduction

## CHD death, non-fatal non procedure-related Ml, resuscitated cardiac arrest, fatal or non-fatal stroke

^ Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): Double-blind, placebo-controlled study including 10,305

hypertensive patients treated with antihypertensive therapy and without a previous MI with TC ≤250 mg/dL (6.4 mmol/L) randomised to LIPITOR^®

10 mg (n=5,168) or placebo (n=5,137). Patients also had ≥3 of the following additional CV risk factors: left ventricular hypertrophy, other specified abnormalities on ECG, type 2 diabetes, peripheral arterial disease, previous stroke or transient ischaemic attack, male sex, age ≥55 years, microalbuminuria or proteinuria, smoking, plasma TC:HDL-C ratio ≥6 or family history of premature CHD. Primary endpoint: non-fatal MI and fatal CHD. Mean baseline LDL-C and HDL-C were 132 and 50 mg/dL (3.4 and 1.3 mmol/L). The ASCOT-LLA study was stopped after 3.3 years of a planned five-year follow-up due to a significant reduction in cardiovascular outcomes among hypertensive patients with normal cholesterol levels who were on Lipitor^® treatment.

ð TNT: Treating to New Targets Investigators

ß Pravastatin or Atorvastatin Evaluation and Infection Therapy

Ω Major CV events: MI, unstable angina requiring hospitalization, revascularization, and stroke

‡ ALLIANCE (Aggressive Lipid-Lowering Initiation Abates New Cardiac Events): Prospective, “real-world” study in which 2,442 patients with known CHD and hyperlipidaemia (LDL-C 110-200 mg/dL [2.8-5.2 mmol/L] for lipid-treated patients, 130-250 mg/dL [3.4-6.5 mmol/L] for untreated patients) were randomised to aggressive treatment with LIPITOR^® (n=1,217) or usual care (n=1,225) and followed for a mean of 51.5 months. LIPITOR^®- treated patients were titrated to LDL-C goals of <80 mg/dL (2.1 mmol/L) or a maximum dose of 80 mg/day. Mean dose of LIPITOR^® was 40.5mg/day. Usual-care patients received any treatment deemed appropriate by their physicians, including lipid-lowering treatment. The primary efficacy endpoint was the time from randomisation to the first occurrence of a primary cardiovascular event (cardiac death, non-fatal MI, resuscitated cardiac arrest, cardiac revascularization or unstable angina requiring hospitalisation).

† Primary CV events: cardiac death, non-fatal MI, resuscitated cardiac arrest, cardiac revascularization and unstable angina requiring hospitalisation.